Patents on P110 and its utility in HD, ALS and other neurodegenerative diseases have been filed by DM‐R and AUJ, and P110 was recently licensed to Mitoconix Bioscience, a company that DM‐R founded and serves on its board, that develops new treatment for Huntington's disease. However, none of the work in her laboratory was carried out in collaboration with or with financial support from the company. AUJ and MS both advised the company, as part of technology transfer to the company, on their work related to Huntington's disease. The other authors declare that they have no conflict of interest.